Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of 6MW3211 in advanced clear cell renal cell carcinoma
CTR20221481Phase 2Terminated
- Sponsor
- Maiwei Biotech
- Start
- Aug 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 6MW3211 in clear cell renal cell carcinoma (ccRCC), sponsored by Maiwei Biotech. Started Aug 2022; status: terminated.
02
Drugs
6MW3211
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20221481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221481.